STOCK TITAN

Krystal Biotech, Inc. - KRYS STOCK NEWS

Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pioneering commercial-stage biotechnology company specializing in the development of innovative gene therapies for skin diseases. Headquartered in Pittsburgh, Pennsylvania, the company leverages its proprietary gene therapy platform, known as STAR-D, to create revolutionary treatments for rare and orphan dermatological conditions caused by genetic mutations.

Krystal Biotech's flagship product, VYJUVEK, is a topical, non-invasive, and redosable gene therapy designed to treat dystrophic epidermolysis bullosa (DEB), a debilitating skin disease characterized by fragile, blistering skin. VYJUVEK delivers the COL7A1 gene directly to the skin, providing the cells with the template to produce normal collagen type VII, thereby addressing the root cause of the disease. This groundbreaking therapy is the first-ever redosable gene therapy approved by the FDA for DEB, marking a significant milestone in genetic medicine.

The company's robust pipeline includes several promising candidates such as KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency, and KB707, an innovative gene therapy for solid tumors. KB707 is notable for its dual-action mechanism, delivering genes encoding interleukin-12 (IL-12) and interleukin-2 (IL-2) to promote tumor clearance. This treatment has received Fast Track Designation from the FDA, reflecting its potential to meet critical unmet medical needs.

Krystal Biotech's commitment to scientific innovation and operational excellence extends to its aesthetic subsidiary, Jeune Aesthetics, Inc., which focuses on reversing the biology of aging and damaged skin.

Recent developments highlight Krystal Biotech's ongoing efforts to expand its global footprint. The company has submitted a Marketing Authorization Application for VYJUVEK to the European Medicines Agency, with a CHMP opinion anticipated in the second half of 2024. Additionally, VYJUVEK has been granted Orphan Drug Designation in Japan, underscoring its potential to address significant unmet medical needs in international markets.

Financial Performance: In 2023, Krystal Biotech reported significant financial growth, driven by the successful launch and robust demand for VYJUVEK in the U.S. market. The company achieved $50.7 million in net product revenue within six months of VYJUVEK's approval, supported by high patient and physician demand, broad access, and compliance.

Krystal Biotech continues to advance its clinical and preclinical pipeline, striving to deliver next-generation genetic medicines across various therapeutic areas, including respiratory, oncology, dermatology, ophthalmology, and aesthetics.

For more information, visit www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston on November 12, 2024. Krish S. Krishnan, Chairman and CEO, will participate in a fireside chat at 1:30 pm ET and conduct investor meetings throughout the day. The presentation will be accessible via webcast and will be available on the company's Investors section of their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.05%
Tags
conferences
-
Rhea-AI Summary

Krystal Biotech (KRYS) reported strong Q3 2024 financial results with net product revenue of $83.8 million and total revenue of $250.1 million since VYJUVEK's launch in August 2023. The company secured over 460 reimbursement approvals in the U.S. with 97% coverage under commercial and Medicaid plans. The quarter ended with $694.2 million in cash and investments. Key developments include JNDA filing for B-VEC in Japan, French early access approval, and positive Phase 1 results for KB301. The company maintained a strong 92% gross margin and reported net income of $27.2 million, or $0.95 per basic share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) has scheduled its third quarter 2024 financial results announcement for Monday, November 4, 2024, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A live webcast will be available, and a replay will be accessible for 30 days on the company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences earnings
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the 2024 Cantor Global Healthcare Conference on September 18, 2024, in New York. Krish S. Krishnan, Chairman and CEO, will engage in a fireside chat at 1:20 pm ET and conduct investor meetings throughout the day.

A webcast of the presentation will be available starting at 1:20 pm ET on Wednesday, September 18, 2024, and will be accessible on the Investors section of the company's website. This event provides an opportunity for Krystal Biotech to showcase its developments and engage with investors in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
conferences
-
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and CEO, will deliver a company presentation at 12:30 pm ET and engage in investor meetings throughout the day.

A webcast of the presentation will be available starting at 12:30 pm ET on Tuesday, September 10, 2024, accessible through a provided link and subsequently posted on the Investors section of the company's website. This event presents an opportunity for Krystal Biotech to showcase its progress and engage with potential investors in a prominent global investment forum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences
-
Rhea-AI Summary

Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), announced positive interim safety and efficacy results from Phase 1 study PEARL-1 for KB301, an investigational aesthetic treatment. The study evaluated KB301 for improving lateral canthal lines and dynamic wrinkles of the décolleté.

Key findings include:

  • 94% of décolleté subjects showed improvement in wrinkles after two months
  • 75% of lateral canthal subjects showed improvement in wrinkles after two months
  • Improvements were also seen in crepiness, hydration, and radiance
  • The safety profile was consistent with prior clinical experience

Based on these results, Jeune will progress KB301 into Phase 2 development for treating dynamic wrinkles of the décolleté. A conference call to discuss results is scheduled for August 28, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) reported strong Q2 2024 financial results, with net product revenue of $70.3 million, up 55.3% from Q1. VYJUVEK, their treatment for Dystrophic Epidermolysis Bullosa, has generated $166.2 million since launch in August 2023. The company secured over 400 reimbursement approvals in the U.S., with 97% positive access determinations for commercial and Medicaid plans. Krystal ended Q2 with $628.9 million in cash and investments.

The company expects three clinical readouts in H2 2024, including KB301 for aesthetics, KB408 for alpha-1 antitrypsin deficiency, and KB707 for solid tumors. Krystal is advancing its pipeline across respiratory, ophthalmology, oncology, and dermatology indications. For FY2024, they anticipate $150-$175 million in non-GAAP R&D and SG&A expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.85%
Tags
-
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced it will release its second quarter 2024 financial results on August 5, 2024, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update.

Investors and the public can access the live webcast at a provided link. For those unable to attend, a replay will be available for 30 days on the company's website. This announcement indicates Krystal Biotech's commitment to transparency and shareholder communication, as it prepares to share its latest financial performance and operational progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences earnings
-
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan will participate in a fireside chat at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
conferences
Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, announced its participation in the American Thoracic Society (ATS) 2024 International Conference from May 17-22 in San Diego, CA. The company will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408. Both are modified, replication-defective, non-integrating HSV-1 vectors designed for inhaled lung delivery via nebulization. KB407 aims to treat cystic fibrosis, while KB408 targets alpha-1 antitrypsin deficiency. Data on these candidates will be shared, including insights from ongoing Phase 1 studies. Poster presentations by Dr. Sara Artusi will provide further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
conferences

FAQ

What is the current stock price of Krystal Biotech (KRYS)?

The current stock price of Krystal Biotech (KRYS) is $181.461 as of November 6, 2024.

What is the market cap of Krystal Biotech (KRYS)?

The market cap of Krystal Biotech (KRYS) is approximately 5.4B.

What does Krystal Biotech, Inc. specialize in?

Krystal Biotech, Inc. specializes in the development of gene therapies for dermatological diseases, focusing on genetic conditions caused by mutations.

What is VYJUVEK?

VYJUVEK is a topical, non-invasive, and redosable gene therapy developed by Krystal Biotech to treat dystrophic epidermolysis bullosa (DEB) by delivering the COL7A1 gene to the skin.

Where is Krystal Biotech headquartered?

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

What are some of Krystal Biotech’s pipeline products?

Krystal Biotech's pipeline includes products like KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency, and KB707 for solid tumors.

What recent achievements has Krystal Biotech accomplished?

Recent achievements include the FDA approval of VYJUVEK, the submission of a Marketing Authorization Application to the European Medicines Agency, and receiving Orphan Drug Designation in Japan.

What is the STAR-D platform?

The STAR-D platform is Krystal Biotech's proprietary gene therapy technology used to develop treatments for rare dermatological conditions caused by genetic mutations.

How has Krystal Biotech performed financially?

In 2023, Krystal Biotech reported $50.7 million in net product revenue from VYJUVEK within six months of its approval, driven by high demand and broad access.

What is Jeune Aesthetics, Inc.?

Jeune Aesthetics, Inc. is a wholly-owned subsidiary of Krystal Biotech focused on developing gene therapies to address aging and damaged skin.

What is KB707?

KB707 is an innovative gene therapy for solid tumors that delivers genes encoding interleukin-12 (IL-12) and interleukin-2 (IL-2) to promote tumor clearance. It has received Fast Track Designation from the FDA.

How can I learn more about Krystal Biotech?

For more information, visit www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.

Krystal Biotech, Inc.

Nasdaq:KRYS

KRYS Rankings

KRYS Stock Data

5.45B
28.76M
12.32%
108.26%
12.32%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PITTSBURGH